sorafenib has been researched along with Mediastinal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J | 1 |
| Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM | 1 |
2 other study(ies) available for sorafenib and Mediastinal Neoplasms
| Article | Year |
|---|---|
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms | 2010 |